TriSalus Life Sciences (TLSI) Gains from Investment Securities (2022 - 2026)

TriSalus Life Sciences' Gains from Investment Securities history runs 5 years deep, the most recent figure standing at -$7.4 million for Q1 2026.

• On a quarterly basis, Gains from Investment Securities fell 1002.68% year-over-year to -$7.4 million in Q1 2026; TTM through Mar 2026 was -$5.5 million, a 61.95% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, up 124.42% from the prior year.
• Gains from Investment Securities slipped to -$7.4 million in Q1 2026 per TLSI's latest filing, from $5.1 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $9.6 million in Q4 2023 and bottomed at -$19.9 million in Q3 2023.
• The 5-year median for Gains from Investment Securities is -$1.5 million (2024), against an average of -$2.4 million.
• Across the five-year window, Gains from Investment Securities surged 520.12% in 2025 and tumbled 1002.68% in 2026, its largest moves.
• Year by year, Gains from Investment Securities stood at -$2.4 million in 2022, then surged by 502.47% to $9.6 million in 2023, then slumped by 91.36% to $830000.0 in 2024, then jumped by 520.12% to $5.1 million in 2025, then plunged by 243.81% to -$7.4 million in 2026.
• Per Business Quant, the three latest TLSI Gains from Investment Securities figures stand at -$7.4 million (Q1 2026), $5.1 million (Q4 2025), and -$2.5 million (Q3 2025).